Supplementary Table 1.docx (13.07 kB)

Supplementary Table – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

dataset

posted on 2021-11-11, 10:00 authored by Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke

Supplementary Table 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

The reasons for dose reduction

Funding

First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

History

Usage metrics

Read the peer-reviewed publication

First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

Future Oncology

Categories

Keywords

Epidermal growth factor receptor Non-small cell lung cancer Osimertinib Performance status Tyrosine kinase inhibitor Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Molecular Targets Solid Tumours

Licence

CC BY-NC-ND 4.0

Exports